MA56289B1 - Mutéines d'interleukine-21 et méthodes de traitement - Google Patents
Mutéines d'interleukine-21 et méthodes de traitementInfo
- Publication number
- MA56289B1 MA56289B1 MA56289A MA56289A MA56289B1 MA 56289 B1 MA56289 B1 MA 56289B1 MA 56289 A MA56289 A MA 56289A MA 56289 A MA56289 A MA 56289A MA 56289 B1 MA56289 B1 MA 56289B1
- Authority
- MA
- Morocco
- Prior art keywords
- muteins
- methods
- interleukin
- treatment methods
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des mutéines d'il-21 et des protéines de fusion les comprenant destinées à être utilisées dans des méthodes de traitement d'une maladie. Des conjugués, des acides nucléiques, des vecteurs, des cellules hôtes, des compositions pharmaceutiques et des kits associés sont en outre décrits. L'invention concerne également des procédés de préparation desdites mutéines d'il-21 et de protéines de fusion les comprenant, ainsi que des méthodes de traitement d'un sujet en ayant besoin. Des protéines de liaison à l'antigène pd-1 sont en outre décrites.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540692P | 2017-08-03 | 2017-08-03 | |
US201862616733P | 2018-01-12 | 2018-01-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA56289A MA56289A (fr) | 2020-06-10 |
MA56289B1 true MA56289B1 (fr) | 2022-04-29 |
Family
ID=63350603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA56289A MA56289B1 (fr) | 2017-08-03 | 2018-08-03 | Mutéines d'interleukine-21 et méthodes de traitement |
Country Status (33)
Country | Link |
---|---|
US (2) | US11541103B2 (fr) |
EP (2) | EP3661954B1 (fr) |
JP (2) | JP7079171B2 (fr) |
KR (2) | KR20220092652A (fr) |
CN (2) | CN111164100B (fr) |
AU (2) | AU2018311079B2 (fr) |
BR (2) | BR112020002013B1 (fr) |
CA (1) | CA3071376A1 (fr) |
CL (2) | CL2020000252A1 (fr) |
CO (1) | CO2020001113A2 (fr) |
CR (1) | CR20200099A (fr) |
CY (1) | CY1125429T1 (fr) |
DK (1) | DK3661954T3 (fr) |
ES (1) | ES2910969T3 (fr) |
HR (1) | HRP20220404T1 (fr) |
HU (1) | HUE058233T2 (fr) |
IL (1) | IL272137A (fr) |
JO (1) | JOP20200020B1 (fr) |
LT (1) | LT3661954T (fr) |
MA (1) | MA56289B1 (fr) |
MX (2) | MX2020001328A (fr) |
MY (1) | MY195974A (fr) |
PH (1) | PH12020500231A1 (fr) |
PL (1) | PL3661954T3 (fr) |
PT (1) | PT3661954T (fr) |
RS (1) | RS63101B1 (fr) |
SA (1) | SA520411230B1 (fr) |
SG (1) | SG11202000821SA (fr) |
SI (1) | SI3661954T1 (fr) |
TN (1) | TN2020000015A1 (fr) |
TW (2) | TWI798245B (fr) |
UY (1) | UY37829A (fr) |
WO (1) | WO2019028316A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3072099A1 (fr) * | 2017-08-11 | 2019-02-14 | Research Development Foundation | Variants d'anticorps fc modifies pour demi-vie serique amelioree |
JP6630026B1 (ja) * | 2018-04-27 | 2020-01-15 | 隆代 大田 | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー |
US20210163562A1 (en) * | 2018-07-25 | 2021-06-03 | AskGene Pharma, Inc. | Novel IL-21 Prodrugs and Methods of Use Thereof |
JP2022514702A (ja) * | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗pd-1/il-7分子 |
SG11202111672RA (en) * | 2019-04-30 | 2021-11-29 | Target Discovery Merger Sub Ii Llc | Cancer associated antibody compositions and methods of use |
AU2020380379A1 (en) * | 2019-11-08 | 2022-05-26 | Amgen Inc. | Engineering charge pair mutations for pairing of hetero-IgG molecules |
WO2021092719A1 (fr) * | 2019-11-11 | 2021-05-20 | 王盛典 | Protéine de fusion ciblant des lymphocytes t spécifiques d'un antigène pour induire leur différenciation en cellules souches de mémoire |
US11692020B2 (en) | 2019-11-20 | 2023-07-04 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
CN111087473B (zh) * | 2019-12-11 | 2022-06-14 | 上海百英生物科技有限公司 | 一种SIRPa-Fc-IL21融合蛋白及其应用 |
CN111925990B (zh) * | 2020-09-02 | 2022-08-26 | 北京立康生命科技有限公司 | 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法 |
AU2021370625A1 (en) * | 2020-10-26 | 2023-06-01 | Oren BESKE | Orthogonal il-21 receptor/cytokine systems |
US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
JP2024500232A (ja) * | 2020-12-23 | 2024-01-05 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | インターロイキン21変異体およびその使用 |
MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
AU2022253351A1 (en) * | 2021-04-09 | 2023-10-12 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
US20240174752A1 (en) | 2021-04-27 | 2024-05-30 | Amgen Inc. | Modulating product quality of asymmetric multispecific antibodies through the use of temperature |
CA3219181A1 (fr) * | 2021-05-19 | 2022-11-24 | Yik Andy Yeung | Polypeptides d'il-21 et constructions ciblees |
WO2022258691A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a |
WO2022258678A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a |
EP4352098A1 (fr) | 2021-06-09 | 2024-04-17 | Innate Pharma | Protéines multispécifiques se liant à nkp46, récepteur de cytokine, antigène tumoral et cd16a |
AU2022324624A1 (en) * | 2021-08-06 | 2024-02-08 | Amgen Inc. | Isolation of therapeutic protein |
AU2022350320A1 (en) * | 2021-09-24 | 2024-04-11 | Bionsystems Inc | Fusion protein dimer including pd-1 and il-21, and use thereof |
US20230136331A1 (en) * | 2021-09-30 | 2023-05-04 | Ildong Pharmaceutical Co., Ltd. | Immunocytokine containing il-21r mutein |
WO2023205738A2 (fr) * | 2022-04-20 | 2023-10-26 | Neptune Biosciences Llc | Systèmes cytokines/récepteurs d'il-21 orthogonaux |
WO2023215829A1 (fr) * | 2022-05-05 | 2023-11-09 | Amgen Inc. | Hétéromultimère se liant à dll3 et cd3 |
KR20230157760A (ko) * | 2022-05-10 | 2023-11-17 | 아주대학교산학협력단 | 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
TW202409068A (zh) * | 2022-06-29 | 2024-03-01 | 大陸商北京星奇原生物科技有限公司 | Il—21多肽和使用方法 |
CN117645669A (zh) * | 2022-08-29 | 2024-03-05 | 星奕昂(上海)生物科技有限公司 | 具有膜结合型il-21的免疫细胞及其制法和应用 |
CN117645661A (zh) * | 2022-09-02 | 2024-03-05 | 北京志道生物科技有限公司 | 一种聚乙二醇修饰的il-21衍生物及其应用 |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (fr) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Animaux non humains transgeniques capables de produire des anticorps heterologues |
US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US5855885A (en) | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
CA2616914C (fr) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Anticorps de liaison de recepteur d'egf |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
KR20010040819A (ko) | 1998-02-10 | 2001-05-15 | 가마꾸라 아끼오 | 제어방출형 제제 |
NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
CA2356937A1 (fr) | 1998-12-31 | 2000-07-13 | Richard J. Whitley | Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
CA2398136A1 (fr) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie |
JP4212897B2 (ja) | 2001-03-27 | 2009-01-21 | 具紀 藤堂 | ウイルスおよび治療法におけるそれらの使用 |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
EP2130919A1 (fr) | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | Antagonistes IL-21 |
DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
PT1576112E (pt) | 2002-01-18 | 2012-05-25 | Zymogenetics Inc | Multímeros de receptor de citocina zcytor17 |
US7736652B2 (en) | 2002-03-21 | 2010-06-15 | The Regents Of The University Of California | Antibody fusion proteins: effective adjuvants of protein vaccination |
EP1531850B1 (fr) | 2002-06-07 | 2012-02-22 | ZymoGenetics, Inc. | Utilisation de l'IL-21 et d'anticorps monoclonal pour le traitement de tumeurs solides |
ATE458534T1 (de) | 2002-10-04 | 2010-03-15 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
CN1513993A (zh) * | 2002-12-31 | 2004-07-21 | 北京博泰迪生物工程科技开发有限公司 | 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列 |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
AU2004275871A1 (en) | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
BRPI0415457A (pt) | 2003-10-16 | 2006-12-05 | Micromet Ag | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
MXPA06014075A (es) | 2004-06-03 | 2007-03-15 | Novimmune Sa | Anticuerpos anti-cd3 y metodos de uso de los mismos. |
US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
JP2008533147A (ja) | 2005-03-14 | 2008-08-21 | メルク エンド カムパニー インコーポレーテッド | Cgrp受容体拮抗薬 |
US8034326B2 (en) | 2005-04-18 | 2011-10-11 | Novo Nordisk A/S | IL-21 variants |
EP3530736A3 (fr) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
WO2007114861A2 (fr) | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Antagonistes du recepteur de il-21 |
US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
EA200802289A1 (ru) | 2006-05-08 | 2009-04-28 | Филоджен Спа | Направляемые к мишени антителами цитокины для терапии |
CA2666426A1 (fr) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Variantes il-21 |
WO2008074863A1 (fr) | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | Variants de l'interleukine-21 avec une liaison modifiée au récepteur de il-21 |
CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
CA2683698C (fr) | 2007-04-19 | 2013-09-10 | Hyun Hee Kwak | Composition de microspheres biodegradables a liberation controlee d'un peptide regulateur du glucose et formule associee |
RU2504552C2 (ru) | 2007-12-07 | 2014-01-20 | Займодженетикс, Инк. | Моноклональные антитела против il-21 человека |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
WO2009127691A1 (fr) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant |
BRPI0919841A2 (pt) | 2008-10-01 | 2014-11-18 | Micromet Ag | Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas |
US20120107267A1 (en) * | 2009-03-11 | 2012-05-03 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
EP2467165B1 (fr) | 2009-08-17 | 2015-01-07 | Roche Glycart AG | Immunoconjugués ciblés |
EP3421491A3 (fr) | 2009-10-30 | 2019-03-27 | Albumedix Ltd | Variantes d'albumine |
DK2542590T4 (da) | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
WO2012059486A1 (fr) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Variants d'albumine |
MX2013009151A (es) | 2011-02-10 | 2013-08-29 | Roche Glycart Ag | Inmunoterapia mejorada. |
AU2012229251A1 (en) | 2011-03-11 | 2013-09-12 | Amgen Inc. | Method of correlated mutational analysis to improve therapeutic antibodies |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US8822417B2 (en) | 2011-05-05 | 2014-09-02 | Novozymes Biopharma DIC A/S | Albumin variants |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
WO2013006795A2 (fr) | 2011-07-07 | 2013-01-10 | Humanitas International Foundation | Compositions antivirales et leurs méthodes d'utilisation |
HUE041799T2 (hu) | 2011-09-08 | 2019-05-28 | Univ New York | Onkolitikus Herpes simplex vírus és terápiás alkalmazásai |
BR112014009925B1 (pt) | 2011-10-28 | 2022-09-20 | Teva Pharmaceuticals Australia Pty Ltd | Construtores de polipeptídeos e seus usos |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
EP2780364A2 (fr) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Protéines ayant une demi-vie et d'autres propriétés améliorées |
WO2013096732A2 (fr) | 2011-12-23 | 2013-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procédé de traitement ou de prévention de maladies virales par blocage de l'interleukine-21 |
WO2013109904A1 (fr) | 2012-01-19 | 2013-07-25 | University Of Miami | Compositions, procédés et série de traitements contre le cancer et des maladies auto-immunes |
BR112014018679A2 (pt) | 2012-03-16 | 2017-07-04 | Novozymes Biopharma Dk As | variantes de albumina |
CN104334573A (zh) | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
EP2847219A1 (fr) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anticorps anti-érythropoïétine |
WO2013169693A1 (fr) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1 |
AU2013301582B2 (en) | 2012-08-07 | 2018-09-06 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
BR112015010318A2 (pt) | 2012-11-08 | 2017-08-22 | Albumedix As | Variantes de albumina |
CN105518143B (zh) | 2013-03-15 | 2020-02-21 | 北京凯得尔森生物技术有限公司 | 融合蛋白分子和它的使用方法 |
AU2014259719B2 (en) | 2013-05-02 | 2019-10-03 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
WO2015000585A1 (fr) * | 2013-07-02 | 2015-01-08 | Walter Sebald | Mutéines de cytokines de la famille des récepteurs de la chaîne gamma conjuguées à un groupe non protéine |
KR102361237B1 (ko) | 2013-07-11 | 2022-02-09 | 더 스크립스 리서치 인스티튜트 | 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물 |
PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
MX2016010174A (es) | 2014-02-06 | 2016-11-15 | Hoffmann La Roche | Proteinas de fusion de interleucina-10 y usos de las mismas. |
CN105992590B (zh) | 2014-02-19 | 2019-12-31 | 默克专利股份公司 | 靶定癌症的il-12免疫疗法 |
CA2948275C (fr) | 2014-04-08 | 2023-10-17 | Boston Pharmaceuticals Inc. | Molecules de liaison specifiques de l'il-21 et leurs utilisations |
CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
PL3233192T3 (pl) | 2014-12-15 | 2021-11-02 | Washington University | Kompozycje i sposoby ukierunkowanego dostarczania cytokin |
WO2016094962A1 (fr) | 2014-12-19 | 2016-06-23 | Monash University | Anticorps il -21 |
WO2016096858A1 (fr) | 2014-12-19 | 2016-06-23 | Mabtech Ab | Composition, kit et procédé servant à l'inhibition de l'activation médiée par il-21 de cellules humaines |
KR20160113452A (ko) | 2015-03-20 | 2016-09-29 | (주)엘지하우시스 | 진공 단열재용 심재 및 진공단열재 |
IL297090A (en) | 2015-07-30 | 2022-12-01 | Macrogenics Inc | Molecules that bind pd-1 and methods of using them |
US20180221503A1 (en) | 2015-07-31 | 2018-08-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
MY187739A (en) | 2015-08-11 | 2021-10-18 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
EP3356404B1 (fr) | 2015-10-02 | 2021-08-18 | F. Hoffmann-La Roche AG | Anticorps anti-pd1 et procédés d'utilisation |
MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
EP3371311B1 (fr) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Protéines chimères bifonctionnelles et leurs utilisations |
HUE063377T2 (hu) * | 2015-12-22 | 2024-01-28 | Regeneron Pharma | Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére |
US10570377B2 (en) | 2016-01-08 | 2020-02-25 | Replimune Limited | Oncolytic virus strain |
US20210000921A1 (en) | 2016-01-11 | 2021-01-07 | Flagship Pioneering Innovations V. Inc. | Methods and compositions for modulating thymic function |
PL3411404T3 (pl) | 2016-02-03 | 2023-02-13 | Amgen Research (Munich) Gmbh | Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T |
US10301391B2 (en) | 2016-02-03 | 2019-05-28 | Amgen Research (Munich) Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
AU2017213659B2 (en) | 2016-02-05 | 2024-04-18 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2017134305A1 (fr) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Agents de signalisation bispécifiques et leurs utilisations |
WO2017158436A1 (fr) | 2016-03-17 | 2017-09-21 | Oslo Universitetssykehus Hf | Protéines de fusion ciblant des macrophages associés aux tumeurs pour le traitement du cancer |
JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス,インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
TN2018000337A1 (en) | 2016-04-01 | 2020-01-16 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
CN112575036A (zh) | 2016-04-22 | 2021-03-30 | 深圳市亦诺微医药科技有限公司 | I型单纯疱疹病毒载体及重组溶瘤性i型单纯疱疹病毒 |
RU2758007C2 (ru) | 2016-06-30 | 2021-10-25 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
WO2018026872A1 (fr) | 2016-08-01 | 2018-02-08 | Virogin Biotech Canada Ltd | Vecteurs de virus de l'herpès simplex oncolytique exprimant des molécules stimulatrices du système immunitaire |
KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
KR102266788B1 (ko) | 2016-09-14 | 2021-06-22 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Pd-1에 특이적으로 결합하는 항체 및 그의 기능성 단편 |
MX2019003058A (es) | 2016-09-21 | 2019-11-28 | Cstone Pharmaceuticals | Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). |
EP3515472A4 (fr) | 2016-09-23 | 2020-04-29 | OncoSec Medical Incorporated | Modulation de réponses à une thérapie par inhibiteur de point de contrôle |
MY195110A (en) | 2016-11-02 | 2023-01-10 | Jounce Therapeutics Inc | Antibodies to PD-1 and uses Thereof |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
CN107082812B (zh) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
UA125700C2 (uk) | 2017-04-03 | 2022-05-18 | Ф. Хоффманн-Ля Рош Аг | Імунокон'югати антитіла до pd-1 з мутантом il-2 |
US11471490B2 (en) | 2017-07-03 | 2022-10-18 | Torque Therapeutics, Inc. | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof |
CN113166220A (zh) | 2018-03-09 | 2021-07-23 | 奥美药业有限公司 | 创新细胞因子前药 |
US20210024631A1 (en) | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
KR20210018797A (ko) | 2018-04-10 | 2021-02-18 | 암젠 인크 | Dll3에 대한 키메라 수용체 및 이의 사용 방법 |
CN113166266A (zh) | 2018-06-18 | 2021-07-23 | 安维塔生物科学股份有限公司 | 抗间皮素构建体及其用途 |
WO2020065096A1 (fr) | 2018-09-28 | 2020-04-02 | Pierre Fabre Medicament | Nouvelles immunocytokines pour le traitement du cancer |
CA3122899A1 (fr) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Molecule bifonctionnelle dirigee contre le pd-1 humain |
-
2018
- 2018-08-03 PT PT187592076T patent/PT3661954T/pt unknown
- 2018-08-03 RS RS20220350A patent/RS63101B1/sr unknown
- 2018-08-03 AU AU2018311079A patent/AU2018311079B2/en active Active
- 2018-08-03 LT LTEPPCT/US2018/045105T patent/LT3661954T/lt unknown
- 2018-08-03 CR CR20200099A patent/CR20200099A/es unknown
- 2018-08-03 SI SI201830619T patent/SI3661954T1/sl unknown
- 2018-08-03 CA CA3071376A patent/CA3071376A1/fr active Pending
- 2018-08-03 PL PL18759207T patent/PL3661954T3/pl unknown
- 2018-08-03 US US16/054,035 patent/US11541103B2/en active Active
- 2018-08-03 EP EP18759207.6A patent/EP3661954B1/fr active Active
- 2018-08-03 SG SG11202000821SA patent/SG11202000821SA/en unknown
- 2018-08-03 JP JP2018146505A patent/JP7079171B2/ja active Active
- 2018-08-03 MY MYPI2020000420A patent/MY195974A/en unknown
- 2018-08-03 CN CN201880064079.0A patent/CN111164100B/zh active Active
- 2018-08-03 TN TNP/2020/000015A patent/TN2020000015A1/en unknown
- 2018-08-03 UY UY0001037829A patent/UY37829A/es not_active Application Discontinuation
- 2018-08-03 DK DK18759207.6T patent/DK3661954T3/da active
- 2018-08-03 KR KR1020227021497A patent/KR20220092652A/ko active Application Filing
- 2018-08-03 TW TW107127071A patent/TWI798245B/zh active
- 2018-08-03 KR KR1020207005850A patent/KR102414120B1/ko active IP Right Grant
- 2018-08-03 EP EP21217086.4A patent/EP4029877B1/fr active Active
- 2018-08-03 MA MA56289A patent/MA56289B1/fr unknown
- 2018-08-03 BR BR112020002013-3A patent/BR112020002013B1/pt active IP Right Grant
- 2018-08-03 JO JOP/2020/0020A patent/JOP20200020B1/ar active
- 2018-08-03 HR HRP20220404TT patent/HRP20220404T1/hr unknown
- 2018-08-03 MX MX2020001328A patent/MX2020001328A/es unknown
- 2018-08-03 ES ES18759207T patent/ES2910969T3/es active Active
- 2018-08-03 TW TW112109111A patent/TW202342501A/zh unknown
- 2018-08-03 WO PCT/US2018/045105 patent/WO2019028316A1/fr active Application Filing
- 2018-08-03 CN CN202410297683.5A patent/CN118126157A/zh active Pending
- 2018-08-03 HU HUE18759207A patent/HUE058233T2/hu unknown
- 2018-08-03 BR BR122021015266-7A patent/BR122021015266B1/pt active IP Right Grant
-
2020
- 2020-01-20 IL IL272137A patent/IL272137A/en unknown
- 2020-01-29 CL CL2020000252A patent/CL2020000252A1/es unknown
- 2020-01-30 PH PH12020500231A patent/PH12020500231A1/en unknown
- 2020-01-30 CO CONC2020/0001113A patent/CO2020001113A2/es unknown
- 2020-01-31 MX MX2023013462A patent/MX2023013462A/es unknown
- 2020-02-03 SA SA520411230A patent/SA520411230B1/ar unknown
-
2022
- 2022-02-04 CL CL2022000300A patent/CL2022000300A1/es unknown
- 2022-04-12 CY CY20221100274T patent/CY1125429T1/el unknown
- 2022-05-19 JP JP2022082089A patent/JP2022116099A/ja active Pending
- 2022-09-07 AU AU2022228122A patent/AU2022228122B2/en active Active
- 2022-12-01 US US18/072,959 patent/US20230381276A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56289A (fr) | Mutéines d'interleukine-21 et méthodes de traitement | |
MA46647A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
MA46506A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
MA43330B1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
MA43461B1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
MA44693A1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA41237B1 (fr) | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers | |
MA42381A (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
MA46022A (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
MA41393A1 (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
MA42294B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA38194A1 (fr) | Anticorps anti-ceacam5 et leurs utilisations | |
MA49155B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
EA202090431A1 (ru) | Мутеины интерлейкина-21 и способы лечения | |
MA46503A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |